Patten & Patten Inc. TN cut its position in shares of Celgene Corp. (NASDAQ:CELG) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,549 shares of the biopharmaceutical company’s stock after selling 1,040 shares during the period. Patten & Patten Inc. TN’s holdings in Celgene Corp. were worth $6,016,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in CELG. Nisa Investment Advisors LLC increased its stake in shares of Celgene Corp. by 9.2% in the third quarter. Nisa Investment Advisors LLC now owns 247,313 shares of the biopharmaceutical company’s stock valued at $25,852,000 after buying an additional 20,900 shares during the period. Capstone Asset Management Co. increased its stake in shares of Celgene Corp. by 2.3% in the third quarter. Capstone Asset Management Co. now owns 106,363 shares of the biopharmaceutical company’s stock valued at $11,118,000 after buying an additional 2,347 shares during the period. Atria Investments LLC increased its stake in shares of Celgene Corp. by 16.7% in the third quarter. Atria Investments LLC now owns 14,232 shares of the biopharmaceutical company’s stock valued at $1,488,000 after buying an additional 2,034 shares during the period. First National Bank of Omaha increased its stake in shares of Celgene Corp. by 52.5% in the third quarter. First National Bank of Omaha now owns 91,255 shares of the biopharmaceutical company’s stock valued at $9,539,000 after buying an additional 31,408 shares during the period. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Celgene Corp. during the third quarter valued at about $1,982,000. Institutional investors and hedge funds own 76.43% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 2.96% on Wednesday, hitting $118.51. The stock had a trading volume of 5,355,580 shares. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00. The firm has a market capitalization of $91.87 billion, a price-to-earnings ratio of 45.01 and a beta of 1.71. The firm has a 50 day moving average of $108.88 and a 200-day moving average of $106.73.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same quarter last year, the business posted $1.23 earnings per share. The firm’s revenue was up 27.8% compared to the same quarter last year. Equities analysts predict that Celgene Corp. will post $5.92 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Celgene Corp. (CELG) Position Reduced by Patten & Patten Inc. TN” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/celgene-corp-celg-position-reduced-by-patten-patten-inc-tn.html.

Several research analysts have recently weighed in on CELG shares. Argus reaffirmed a “buy” rating and set a $155.00 price objective on shares of Celgene Corp. in a research report on Wednesday, September 7th. Leerink Swann reaffirmed a “market perform” rating and set a $135.00 price objective on shares of Celgene Corp. in a research report on Monday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Vetr cut Celgene Corp. from a “buy” rating to a “hold” rating and set a $125.81 price objective for the company. in a research report on Monday. Finally, Oppenheimer Holdings Inc. started coverage on Celgene Corp. in a research report on Tuesday. They set an “outperform” rating and a $141.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $136.62.

In related news, Director Richard W. Barker sold 20,000 shares of the stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $110.82, for a total value of $2,216,400.00. Following the sale, the director now owns 31,332 shares in the company, valued at $3,472,212.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,710 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the sale, the director now owns 72,142 shares in the company, valued at approximately $7,678,794.48. The disclosure for this sale can be found here. 0.97% of the stock is owned by corporate insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.